论文部分内容阅读
[目的]观察紫杉醇脂质体在乳腺癌新辅助化疗中的疗效、毒副反应。[方法]回顾性分析20例局部晚期乳腺癌患者含紫杉醇脂质体方案新辅助化疗的疗效、毒副作用。化疗方案为紫杉醇脂质体加表阿霉素,21d为一周期,术前化疗2～6个周期,评估肿瘤缓解情况及毒副反应。[结果]化疗有效率为90%,其中CR3例,PR15例,SD1例,PD1例,达pCR1例。[结论]紫杉醇脂质体联合表阿霉素方案在乳腺癌的新辅助化疗中疗效肯定,毒副反应低,值得进一步研究。
[Objective] To observe the efficacy and side effects of paclitaxel liposomes in neoadjuvant chemotherapy of breast cancer. [Methods] The efficacy and side effects of neoadjuvant chemotherapy with paclitaxel liposomes in 20 patients with locally advanced breast cancer were retrospectively analyzed. Chemotherapy regimens for paclitaxel liposome plus epirubicin, 21d for a cycle, preoperative chemotherapy for 2 to 6 cycles to assess the tumor response and adverse reactions. [Results] The effective rate of chemotherapy was 90%, of which CR3, PR15, SD1, PD1, up to pCR1 cases. [Conclusion] paclitaxel liposomes combined with epirubicin regimen in the efficacy of neoadjuvant chemotherapy in breast cancer affirmation, low toxicity, it is worth further study.